A Hydrogel May End Frequent Injections for Eye Diseases

An innovative drug delivery system may help reduce inflammation and enhance vision protection, according to new research involving mouse models.

MicroScience/Shutterstock

Blindness may no longer be a threat for millions suffering from two devastating eye diseases.

A new study possibly brings hope to the nearly 20 million Americans afflicted with age-related macular degeneration and the close to 100,000 with retinitis pigmentosa. Researchers have developed a novel therapy that could “considerably delay” vision loss.

Frequent Shots Only Option for Blinding Eye Diseases

Age-related macular degeneration (AMD) and retinitis pigmentosa (RP) significantly threaten vision, especially in older adults. AMD affects the central retina’s macula and is a leading cause of blindness in those over 65. RP is a genetic disorder causing progressive photoreceptor death, initially causing night blindness but eventually total vision loss.